⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABBV News
ABBVIE INC.
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight
globenewswire.com
PFE
NVO
AGIO
FCRX
BLUE
ALXN
Takeda
REGN
BEAM
EDIT
SANG
SRPT
CRSP
XENE
GILD
AMGN
BMRA
BIIB
ACRX
AZN
SNY
ROCHE
CSL
SANA
INVO
VRTX
ABBV
LLY
JNJ
MRK
BMY
MDCO
PTLA
RHHBY
BCLI
CELG
NBIX
ALNY
SPRC
ACST
ADPT
AMTX
APLS
ARNA
ATRC
AVEO
AXSM
BPMC
CDMO
CLVS
CNCE
CRBP
CTIC
CYTK
DFFN
DOCU
DRNA
DTIL
EARS
EBAY
ECHO
EGRX
ENDP
ENZ
EPZM
ESRX
EXAS
FGEN
FMI
FRPT
FTNT
GALT
GENE
GNTX
GRFS
GSK
HALO
HAYW
HBMD
HGEN
HLTH
HPE
HTGM
ICPT
IDXX
ILMN
IMCR
IMNX
INCY
IND
INTC
INTU
IOVA
IRTC
ISRG
ITCI
JAZZ
KDP
KHC
KODK
LAKE
LULU
LPTX
LSCC
LX
LYFT
MARA
MCRB
MDLZ
MED
MELI
MGM
MITK
MLNX
MNST
MRVL
MSFT
MTCH
MU
MXIM
MYL
NCLH
NDSN
NET
NEWM
NFLX
NKE
NOC
NOV
NTES
NVDA
NXPI
OBLN
OC
ODFL
OLED
OMER
ON
ONDK
ORCL
ORGN
OSUR
OTIS
OXBR
PACB
PANW
PAYX
PCAR
PCG
PDD
PEGA
PEP
PGR
PGRD
PHG
PI
PINS
PLAB
PLAY
PLRX
PM
PNRA
PPC
PPD
PRGS
PRGO
PRKR
PRO
PRTA
PSN
PTC
PTCT
PTON
PUBG
PVH
QCOM
QGEN
QLGN
QLYS
QTRX
RARE
RCL
RDNT
REMY
RFMD
RGEN
RH
RIBT
RIG
RLAY
RMBS
RMD
ROST
RPTP
RS
RSP
RTX
RUN
RVMD
RYAAY
SAGE
SAN
SBAC
SBEA
SCLX
SCWX
SD
SE
SEIC
SELB
SGEN
SGH
SHCR
SHPG
SI
SIRI
SITE
SIVB
SKX
SLAB
SLGN
SMCI
SMMR
SMPL
SNBR
SNOW
SOFI
SOL
SONO
SOUN
SPCE
SPG
SPLK
SPOT
SQ
SQM
SRDX
SSYS
ST
STAG
STAR
STCN
STLD
STNG
STOK
STOR
STX
SUMO
SWAV
SWCH
SWKS
SYK
SYMC
SYNH
SYRS
T
TAL
TBBK
TBC
TCL
TDOC
TEAM
TECK
TEVA
TFX
TGT
THC
THMO
TIDAL
TIVO
TISI
TLRY
TMO
TMUS
TNDM
TNG
TNK
TORM
TPIC
TPRG
TR
TRC
TRG
TRIP
TRMB
TRN
TROX
TSCO
TSE
TSLA
TSN
TTD
TTC
TTWO
TUSK
TVTY
TXN
TXRH
TYL
U
UAL
UAN
UBER
UHAL
ULTA
UMC
UNFI
UNH
UNIT
UNM
URBN
USFD
USI
USNA
UTHR
V
VAL
VAR
VBIV
VCEL
VCNX
VCR
VCSH
VCTR
VEC
VECO
VEL
VEN
VER
VERU
VFC
VFH
VHT
VICR
VIPS
VIRC
VRT
VSH
VSTM
VTGN
VTRS
VTR
VTWV
VVNT
VY
W
WAB
WBA
WDC
WEC
WELL
WEN
WERN
WEX
WFC
WGO
WHR
WIA
WMB
WMT
WNC
WNR
WPC
WRB
WST
WTAI
WTI
WTW
WU
WY
WYNN
X
XCEL
XCUR
XELA
XOM
XPER
XPO
XRAY
XRO
XRT
XTL
XYL
YELL
YETI
YEXT
YMM
YNDX
YRC
YUM
Z
ZBH
ZBRA
ZGNX
ZION
ZLAT
ZNH
ZNTE
ZOM
ZRO
ZSAN
ZTO
ZTS
ZUO
Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma
globenewswire.com
ABBV
ARCC
GSK
JNJ
REGN
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
globenewswire.com
LUN
LLY
AMGN
NVS
TEVA
ALLER
BHVN
DRREDDY
ABBV
IMPL
ZSAN
AXSM
AEON
IONS
CHRC
AZN
GSK
WSTN
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
prnewswire.com
ABBV
À l'occasion du 19e Congrès européen sur les céphalées, AbbVie va présenter les données de la phase 3 d'ECLIPSE démontrant la supériorité de l'atogépant (AQUIPTA®) par rapport au placebo dans le soulagement complet de la douleur pour le traitement aigu de
prnewswire.com
ABBV
AbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Akutbehandlung von Migräne belegen USA - Deutsch USA - English
prnewswire.com
ABBV
Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
prnewswire.com
AGN
NOVN
EXEL
ABBV
BMY
EISAY
TKPY
MRK
AbbVie presentará datos de fase 3 de ECLIPSE en el 19º Congreso Europeo de Cefaleas USA - español USA - English
prnewswire.com
ABBV
Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
prnewswire.com
ABBV
GILD
BMY
REGN
XBI
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
prnewswire.com
ABBV